Lutetium (177Lu) chloride
Lutetium (177Lu) chloride
Lutetium (177Lu) chloride is a radioactive compound used in nuclear medicine for radiotherapy and diagnostic imaging. It is composed of the isotope Lutetium-177 and chloride ions. This compound is particularly significant in the treatment of certain types of cancer, including neuroendocrine tumors and prostate cancer.
Properties[edit | edit source]
Lutetium-177 is a beta emitter with a half-life of approximately 6.65 days. It decays to stable Hafnium-177 through the emission of beta particles and gamma radiation. The beta particles are effective in destroying cancer cells, while the gamma radiation can be used for imaging purposes.
Applications[edit | edit source]
Lutetium (177Lu) chloride is primarily used in targeted radionuclide therapy. It is often conjugated with peptides or antibodies that specifically target cancer cells, allowing for precise delivery of radiation to the tumor site while minimizing damage to surrounding healthy tissue.
Neuroendocrine Tumors[edit | edit source]
One of the most common applications of Lutetium (177Lu) chloride is in the treatment of neuroendocrine tumors. These tumors can be targeted using peptide receptor radionuclide therapy (PRRT), where the compound is linked to a peptide that binds to receptors on the tumor cells.
Prostate Cancer[edit | edit source]
Lutetium (177Lu) chloride is also used in the treatment of prostate cancer, particularly in cases where the cancer has spread to other parts of the body. It is often linked to molecules that target prostate-specific membrane antigen (PSMA), a protein commonly found on prostate cancer cells.
Production[edit | edit source]
Lutetium-177 is typically produced in a nuclear reactor through the irradiation of Ytterbium-176 or Lutetium-176. The resulting Lutetium-177 is then chemically separated and combined with chloride ions to form Lutetium (177Lu) chloride.
Safety and Handling[edit | edit source]
As a radioactive substance, Lutetium (177Lu) chloride must be handled with care. Proper radiation protection measures, including the use of lead shielding and personal protective equipment, are essential to minimize exposure to radiation.
Related Pages[edit | edit source]
- Nuclear medicine
- Radiotherapy
- Neuroendocrine tumors
- Prostate cancer
- Peptide receptor radionuclide therapy
- Prostate-specific membrane antigen
- Beta emitter
- Gamma radiation
Categories[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
